How Long Does the Hepatitis B Vaccine Last?

For most healthy people, the hepatitis B vaccine provides protection that lasts at least 30 to 35 years and likely much longer. The longest-running cohort study in the world, which followed vaccinated individuals for 35 years, found that 86% still had protective antibody levels or responded robustly when given a booster dose, and no chronic infections developed in the group. The catch is that “how long it lasts” depends on what you mean by lasting, because antibody levels in your blood and actual protection against the virus are not the same thing.

What the Longest Studies Actually Show

Two landmark follow-up studies give us the best picture of long-term vaccine durability. A 35-year cohort study, the longest ever conducted for hepatitis B vaccination, found that protection continued throughout the entire follow-up period. Among people who originally responded to the vaccine, 86% either maintained antibody levels above the standard protective threshold or mounted a strong response when given a single booster dose decades later. No chronic hepatitis B infections were documented in the group.¹

A separate 30-year follow-up study found similar results. Among people who responded to the original vaccine series and never received additional doses, about half still had measurable antibody levels above the protective cutoff three decades later. That sounds low until you factor in the booster response: 88% of those whose antibodies had dropped below the threshold responded to a single booster dose within 30 days. Adding those groups together, the researchers estimated that over 90% of participants still had evidence of protection after 30 years. Their conclusion was straightforward: booster doses are not needed.²

Why Falling Antibody Levels Do Not Mean You Are Unprotected

This is the piece that confuses a lot of people, and reasonably so. If you get a blood test years after vaccination and your anti-HBs level comes back below 10 mIU/mL (the standard “protective” cutoff), it looks like your immunity has worn off. But that number reflects circulating antibodies, not the full picture of your immune defenses. Your immune system also stores memory T cells and memory B cells that can rapidly produce new antibodies when they encounter the actual virus.

A study of vaccinees who had completely lost detectable antibodies found that all of them still had significant numbers of hepatitis B-specific memory T and B cells. When these individuals were given a booster, the T cells triggered the B cells to quickly ramp up antibody production.³ This is sometimes called an “anamnestic response,” but the plain version is that your immune system remembers the virus even when the patrol antibodies have stood down.

Research in Thai infants vaccinated at birth and followed for 20 years illustrated this clearly. When given a challenge dose at the 20-year mark, 93% of unboosted subjects and 100% of previously boosted subjects mounted a strong antibody response, regardless of whether they had measurable antibodies beforehand.⁴ An Italian study of people vaccinated as either infants or adolescents found that about 94% of those with low antibodies mounted an anamnestic response when boosted 18 to 19 years later.⁵

A broad review of published data from many studies reinforced this pattern. Vaccinees who no longer had detectable antibodies still developed rapid anamnestic responses within five to seven days of a challenge dose. Circulating B cells could still produce anti-HBs even when blood tests showed none. The accumulated evidence pointed to a consistent conclusion: despite antibody decline or loss, immune memory persists long term.⁶

People Vaccinated As Infants

If you were vaccinated as a baby, you might wonder whether those infant doses still count decades later. Antibody levels do tend to fade faster in people vaccinated at birth compared to those vaccinated later in childhood or as adults, in part because the neonatal immune system generates a weaker initial antibody peak. A U.S. study of teenagers aged 16 to 19 who had been vaccinated as infants found that only 24% still had protective antibody levels at baseline. But when they were given a single challenge dose, 92% responded with protective levels, confirming that immune memory was intact.⁷

Children followed for seven to eight years after a combination infant vaccine series showed a similar pattern: only about 45% had protective antibody levels at baseline, but after a challenge dose, 99.5% reached protective levels, with antibody concentrations jumping roughly 71-fold over baseline. A 20-year follow-up of newborns who received combined active-passive immunization (vaccine plus hepatitis B immune globulin at birth, typically given when the mother is a carrier) found persistent protection through adolescence despite frequent waning of antibodies, and the researchers concluded no booster was needed during that period.⁸ Earlier work tracking children born to highly infectious mothers reached the same conclusion: protection persisted to age 10 and immune memory was detectable in every subject tested, including those with undetectable antibodies.⁹

The practical takeaway is that having low or undetectable antibodies as a young adult does not mean your childhood vaccination failed. For most people, the memory cells are still there, ready to respond if the virus shows up.

Healthcare Workers and Other High-Exposure Groups

Healthcare workers get asked about hepatitis B immunity more than almost anyone, often because employers require documentation. The question they face is whether they need periodic retesting or booster doses to stay protected on the job. The evidence says no, at least not routinely. A study that tracked healthcare workers from 3 to 13 years after their original vaccine series found that all of them responded to a booster dose, supporting the position that immunized healthcare workers do not need periodic antibody testing or boosters.¹⁰

That said, antibody levels do decline over time. A study of healthcare workers comparing those vaccinated more than five years ago with those vaccinated within the last five years found significantly lower average antibody levels in the group with more time since vaccination. Among those who had received a booster, antibody levels were markedly higher than in those who had not.¹¹ Another study of healthcare students tested 18 years after their primary vaccination found that only about 41% had adequate antibody levels. But when those with low levels received a booster, 94% developed protective levels.¹²

The pattern here matches the general population data: antibodies fade, but immune memory stays. Some healthcare institutions still check antibody levels at hire and offer a booster if they are low, which is reasonable as a belt-and-suspenders approach for people with ongoing occupational exposure. But the data consistently show that a previously vaccinated healthcare worker who responds to a booster is protected, and the vast majority do respond.

When Protection Genuinely Falls Short

Not everyone responds equally to the hepatitis B vaccine, and certain groups lose protection faster or never build it adequately in the first place. People on hemodialysis are the best-studied example. Their immune systems are suppressed by kidney failure, and they tend to produce lower antibody levels after vaccination that decline more quickly. A Chinese study of hemodialysis patients found that only about 75% maintained protective antibody levels at 12 months after the standard dose, and the higher-dose regimen extended that to 18 months. Patients who had been on dialysis for five years or longer fared worse.¹³ A separate trial in pre-hemodialysis and hemodialysis patients found that an adjuvanted vaccine formulation reduced the number of people needing a booster compared to the standard vaccine, but both groups still had higher rates of antibody loss than healthy individuals.¹⁴

Other groups with weakened immune systems, including organ transplant recipients on immunosuppressive drugs, people with advanced HIV, and patients undergoing chemotherapy, also tend to have reduced and shorter-lived vaccine responses. For these populations, regular monitoring of antibody levels and booster doses when levels drop are standard practice, unlike the general population where neither is routinely recommended.

Newer Vaccine Formulations

The hepatitis B vaccine landscape has evolved since the original recombinant vaccines were introduced in the 1980s. A newer formulation called Heplisav-B uses a different type of immune-stimulating ingredient (a CpG adjuvant rather than the traditional aluminum-based one) and requires only two doses instead of three. In a study comparing Heplisav-B with the traditional vaccine as a booster for healthcare workers, a single booster dose achieved protective antibody levels in about 99% of the Heplisav-B group compared to about 93% in the standard vaccine group.¹⁵

In people with chronic kidney disease, Heplisav-B produced higher average antibody concentrations over time than the traditional vaccine, and a larger proportion of recipients maintained concentrations above 100 mIU/mL for longer.¹⁶ Whether these higher initial antibody levels translate into meaningfully longer real-world protection is still being studied, but the early data are promising, particularly for people who historically respond poorly to the standard vaccine.

How Fast Antibodies Decline and What Drives It

If you are curious about the actual rate of antibody decline, a study of over 460 young adults who had been vaccinated as infants found that anti-HBs levels dropped at an average rate of about 42 mIU/mL per year. People who started with higher antibody levels (between 100 and 1,000 mIU/mL) lost them faster in absolute terms, declining at roughly 86 mIU/mL per year, while those starting with lower levels (10 to 100 mIU/mL) declined at about 6 mIU/mL per year.¹⁷ This might seem alarming for the high-responder group, but the faster absolute decline happens precisely because they start with more antibodies. In percentage terms, everyone’s antibodies are fading on a similar curve. And as covered earlier, low antibodies do not equal lost protection.

The 35-year cohort study confirmed that both age at primary vaccination and the initial antibody peak after the primary series correlated with antibody levels decades later.¹ In general, people vaccinated as older children, adolescents, or young adults tend to develop higher initial antibody levels than those vaccinated at birth, and higher initial peaks track with higher levels years later. Other factors that can influence how strong and durable your response is include obesity, smoking, certain genetic variations in immune-system genes, and whether you completed the full vaccine series on schedule.

Vaccine Escape Mutants

A question that gets less public attention but concerns virologists is whether the hepatitis B virus can mutate its way around vaccine-induced immunity. The vaccine works by training the immune system to recognize a specific protein on the virus surface. If that protein changes enough, the antibodies generated by vaccination might not recognize the mutant virus. This is not hypothetical. A well-known mutation called G145R, first identified in Italy about 25 years ago in infants who developed breakthrough infections despite receiving both vaccine and hepatitis B immune globulin at birth, alters the virus surface protein enough that standard vaccine-induced antibodies no longer bind effectively.⁶

Surveillance in Taiwan, which was one of the first countries to implement universal infant hepatitis B vaccination, found that among vaccinated individuals with breakthrough infections, specific surface-gene mutations accounted for a substantial share of the mutant viruses detected. High maternal viral load and intrauterine infection were among the main risk factors for these breakthroughs.¹⁸ Other surface antigen mutations capable of evading vaccine-induced immunity have been documented worldwide, and the concern has been raised that widespread vaccination programs could inadvertently select for these escape variants over time.¹⁹

Before this starts sounding alarming: the overall impact of vaccine escape mutants remains low. Comprehensive reviews have concluded that these mutants do not currently pose a public health threat and do not warrant changes to existing vaccination programs.⁶ They matter most in very specific clinical scenarios, particularly mother-to-child transmission when the mother has a high viral load. For the typical vaccinated person, escape mutants are a theoretical concern being monitored rather than a practical worry.

Do You Need a Booster?

For the average healthy person who completed the standard vaccine series and responded to it, the consistent answer from decades of research is no. No major public health authority currently recommends routine booster doses for immunocompetent people. The immune memory data support this: even when blood tests show low or undetectable antibodies, the vast majority of vaccinated people mount a rapid protective response upon re-exposure to the virus or a booster dose.

The exceptions are specific and well-defined. People on hemodialysis typically need their antibody levels monitored annually and may need boosters when they drop below the protective threshold. Immunocompromised individuals should discuss monitoring schedules with their doctors. For healthcare workers, many institutional policies call for a baseline antibody check at the time of hire, with a booster offered if levels are low, though the evidence suggests this is more cautious than strictly necessary.

If you were vaccinated as a child and are now an adult wondering whether you are still protected, the most likely answer is yes. A blood test showing low antibodies does not mean your immunity has vanished. It means the standing army has gone home, but the reserves can be called up quickly. Whether that framing is comforting or unsettling probably depends on your risk tolerance, but the epidemiological evidence is firmly on the side of lasting protection.

The Booster Question for Children Born to Carrier Mothers

Children born to mothers who carry hepatitis B face a higher risk of infection at birth and are given both the vaccine and hepatitis B immune globulin in the first hours of life. For these children, the question of whether protection lasts is especially high-stakes. The evidence is reassuring. A 20-year follow-up of newborns who received this combined regimen found persistent protection into adolescence, with no need for a booster before that point.⁸ Earlier studies following children of highly infectious mothers to age 5 and age 10 reached the same conclusion: protection held and immune memory was intact in all subjects tested.²⁰⁹

A cost-effectiveness analysis from China examined whether proactive screening and boosting of children born to carrier mothers would be worthwhile compared to the current practice of no routine screening or boosting. Both booster strategies turned out to be cost-saving, meaning they paid for themselves through prevented infections and their downstream healthcare costs. Even in a worst-case scenario where all parameters were set to their least favorable values, the cost per quality-adjusted life-year gained remained well below the threshold for a cost-effective intervention.²¹ This is one area where the “no booster needed” consensus might evolve, at least for targeted populations in high-prevalence regions.